Minoru Takada

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe et al. · The Lancet Oncology · 2009 · 4.1K citations

Open Label, Medicine, Cancer Growth +10

Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104

Minoru Takada, Masahiro Fukuoka, Masaaki Kawahara et al. · Journal of Clinical Oncology · 2002 · 692 citations

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

Kimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto et al. · Science Translational Medicine · 2011 · 658 citations

Cetuximab Sensitivity, Oncology, Erbb2 Signaling +15

Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)

Shinzoh Kudoh, Koji Takeda, Kazuhiko Nakagawa et al. · Journal of Clinical Oncology · 2006 · 365 citations · Full text

Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis of 26,957 Patients with NSCLC

Tomoya Kawaguchi, Minoru Takada, Akihito Kubo et al. · Journal of Thoracic Oncology · 2010 · 351 citations

Tobacco Control, Advanced Lung Disease, Medicine +9